Technical Analysis for NCNA - NuCana plc

Grade Last Price % Change Price Change
grade F 5.0 2.04% 0.10
NCNA closed up 2.04 percent on Thursday, September 24, 2020, on 28 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions.

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Down Down
Historical NCNA trend table...

Date Alert Name Type % Chg
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 0.00%
Calm After Storm Range Contraction 0.00%
NR7 Range Contraction 0.00%
Slingshot Bearish Bearish Swing Setup 2.04%
Stochastic Buy Signal Bullish 2.04%
Calm After Storm Range Contraction 2.04%
Lower Bollinger Band Walk Weakness 2.04%
Oversold Stochastic Weakness 2.04%
Calm After Storm Range Contraction 8.46%
Lower Bollinger Band Walk Weakness 8.46%
Older End-of-Day Gignals for NCNA ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
60 Minute Opening Range Breakout about 5 hours ago
Down 1% about 7 hours ago
Up 2% about 7 hours ago
Up 1% about 7 hours ago
10 DMA Resistance 1 day ago
View Earlier Intraday Alerts

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

NuCana PLC is a clinical-stage biopharmaceutical company. The Company is focused on improving treatment outcomes for cancer patients by applying its phosphoramidate chemistry technology. The Company utilizes its ProTide technology to develop medicines to overcome cancer resistance mechanisms and generate much higher concentrations of anti-cancer metabolites in cancer cells. Its pipeline of products includes Acelarin, NUC-3373 and NUC-7738. Acelarin is a nucleotide analog and is a ProTide transformation of gemcitabine for the treatment of cancer. The Company is evaluating Acelarin in four clinical trials across several solid tumor indications. NUC-3373 is a ProTide transformation of the active anti-cancer metabolite of 5-fluorouracil for the treatment of a wide range of cancers. NUC-3373 is in a Phase I trial for the potential treatment of a wide range of solid tumor cancers. NUC-7738 is a ProTide transformation of cordycepin, a novel nucleoside analog.

Is NCNA a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 10.59
52 Week Low 3.81
Average Volume 251,128
200-Day Moving Average 5.64
50-Day Moving Average 5.46
20-Day Moving Average 5.27
10-Day Moving Average 5.07
Average True Range 0.38
ADX 13.51
+DI 19.79
-DI 20.63
Chandelier Exit (Long, 3 ATRs ) 4.76
Chandelier Exit (Short, 3 ATRs ) 5.64
Upper Bollinger Band 5.98
Lower Bollinger Band 4.55
Percent B (%b) 0.31
BandWidth 27.09
MACD Line -0.19
MACD Signal Line -0.14
MACD Histogram -0.0557
Fundamentals Value
Market Cap 159.06 Million
Num Shares 31.8 Million
EPS -0.40
Price-to-Earnings (P/E) Ratio -12.50
Price-to-Sales 0.00
Price-to-Book 0.00
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 5.34
Resistance 3 (R3) 5.31 5.17 5.28
Resistance 2 (R2) 5.17 5.08 5.18 5.26
Resistance 1 (R1) 5.08 5.03 5.13 5.11 5.24
Pivot Point 4.94 4.94 4.96 4.96 4.94
Support 1 (S1) 4.86 4.86 4.90 4.89 4.76
Support 2 (S2) 4.72 4.80 4.73 4.74
Support 3 (S3) 4.63 4.72 4.72
Support 4 (S4) 4.66